How to Bone morphogenetic protein 2?

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

155 results about "Bone morphogenetic protein 2" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Bone morphogenetic protein 2 or BMP-2 belongs to the TGF-β superfamily of proteins.

Naphtholactams and lactones as bone morphogenetic protein active agents

InactiveUS6030967AHigh toxicological thresholdReduce riskBiocideOrganic chemistryActive agentCarbon chain

PCT No. PCT / JP97 / 02858 Sec. 371 Date Oct. 30, 1997 Sec. 102(e) Date Oct. 30, 1997 PCT Filed Aug. 19, 1997 PCT Pub. No. WO98 / 07705 PCT Pub. Date Feb. 26, 1998A compound of the formula: wherein Q is an optionally substituted carbon atom or N(O)p wherein p is 0 or 1; Y is an optionally substituted methylene group, S(O)q wherein q is an integer of 0 to 2, or an optionally substituted imino group; Z1 is a C1-3 alkylene group which may have an oxo group or a thioxo group and may contain etherified oxygen or sulfur within the carbon chain; Z2 is an optionally substituted C1-3 alkylene group; Ar is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; one of R1 and R2 is a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted lower alkyl group, or an optionally substituted lower alkoxy group; the other is a halogen atom, a hydroxyl group, an optionally substituted lower alkyl group, or an optionally substituted lower alkoxy group; or R1 and R2 taken together with adjacent -c=c- form a ring; and ring A is a benzene ring which may be substituted in addition to R1 and R2; or a salt thereof.

Owner:TAKEDA PHARMA CO LTD

Use of morphogenetic proteins to treat human disc disease

InactiveUS7435260B2Bone implantDiagnosticsDiseaseImmune depression

Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and / or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s).

Owner:ANOVA

Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases

ActiveUS20150139983A1Organic active ingredientsNervous disorderMorphogenesisDisease cause

The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.

155 results about "Bone morphogenetic protein 2" patented technology

Popular searches